M2I LIFE SCIENCE A EUROPEAN INNOVATION PARTNER IN THE MAKING

摘要

In the Formulation area, M2i Pharma now concentrates on Injectable and Tablet starting from readily accessible synthetic raw materials. Chemical Capacities development M2i-Development will continue to offer and expand its expertise in process development with new capabilities in peptide synthesis and continuous flow chemistry. Further details on this work will be available by the end of 2013. M2i-Salin is currently finishing the implementation of a new cGMP Kilo-lab, allowing the group to offer small GMP batches to cover pre-clinical, early phase developments and small-scale industrial needs.